ACUT logo

AccuStem Sciences, Inc. Stock Price

OTCPK:ACUT Community·US$4.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ACUT Share Price Performance

US$0.26
-0.20 (-43.93%)
US$0.26
-0.20 (-43.93%)
Price US$0.26

ACUT Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with weak fundamentals.

6 Risks
0 Rewards

AccuStem Sciences, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$1.8m

Other Expenses

-US$1.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.11
0%
0%
-0.7%
View Full Analysis

About ACUT

Founded
2013
Employees
4
CEO
Wendy Blosser
WebsiteView website
accustem.com

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

Recent ACUT News & Updates

Recent updates

No updates